Genentech Earns Priority Review for Pirfenidone for Unclassifiable Interstitial Lung DiseaseFollowing Positive Clinical Data

Application was based on results of a 24 week phase II RCT (n=153) which showed a significantly lower predicted mean change in FVC vs placebo (treatment difference=95.3 mL; p=0.002). Treatment with pirfenidone was associated with less loss of exercise capacity and lung function.

Source:

Biospace Inc.